Effect of Fasting, Endogenous GLP-1 Secretion on B-cell Response to Intravenous Glucose


About this study

The purpose of this study is to determine the effect of GLP-1 in priming β-cells for insulin secretion.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • BMI 18 – 35  Kg/M2
  •  Fifteen patients with normal glucose tolerance and fifteen with impaired fasting glucose
  • Participants will be in good health
  • Stable weight
  • Not engaged in regular vigorous exercise
  • No history of diabetes or of prior therapy with antidiabetic medication
  • No history of chronic disease
  • No prior abdominal surgery other than cholecystectomy or appendectomy

Exclusion Criteria:

  • Subjects < 20 years of age or > 65 years of age


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer